Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Barclays PLC

Barclays PLC boosted its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 353.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 54,166 shares of the company's stock after buying an additional 42,224 shares during the period. Barclays PLC owned approximately 0.09% of Ginkgo Bioworks worth $531,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Erste Asset Management GmbH lifted its stake in Ginkgo Bioworks by 47.9% in the fourth quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after purchasing an additional 239,332 shares during the last quarter. Forbes J M & Co. LLP raised its holdings in shares of Ginkgo Bioworks by 461.4% in the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after buying an additional 576,732 shares during the period. Geode Capital Management LLC lifted its stake in shares of Ginkgo Bioworks by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 437,025 shares of the company's stock worth $4,294,000 after acquiring an additional 20,394 shares during the last quarter. Monaco Asset Management SAM grew its position in Ginkgo Bioworks by 3.9% in the 4th quarter. Monaco Asset Management SAM now owns 384,664 shares of the company's stock valued at $3,777,000 after acquiring an additional 14,539 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. increased its stake in Ginkgo Bioworks by 33.1% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 361,750 shares of the company's stock worth $3,552,000 after purchasing an additional 90,000 shares during the period. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Trading Down 1.9%

Shares of DNA traded down $0.16 during trading hours on Wednesday, reaching $7.97. 450,321 shares of the company traded hands, compared to its average volume of 1,555,515. The stock's fifty day moving average price is $7.13 and its 200 day moving average price is $9.08. The firm has a market cap of $462.24 million, a price-to-earnings ratio of -0.61 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $37.26.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The company had revenue of $48.32 million for the quarter, compared to analysts' expectations of $38.70 million. On average, research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.